Aragon Pharmaceuticals Announces First Patient Dosed in ARN-810 Phase 1 Study

Aragon Pharmaceuticals Inc., a company that develops drugs to treat hormone-driven cancers, announced that the first patient has been hosed in the clinical study of ARN-810 (Phase 1), which is categorized as an oral selective estrogen receptor degrader to treat breast cancer.

As quoted in the press release:

The Phase 1 dose escalation study is designed to assess safety and tolerability of ARN-810. The study will be conducted at Vanderbilt University, Mass General Hospital and Memorial Sloan-Kettering Cancer Center.

Click here to read the full Aragon Pharmaceuticals Inc. press release.